Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Heparin binds to antithrombin III, accelerating its inactivation of thrombin (factor IIa) and factor Xa, thereby inhibiting coagulation.
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
Prophylaxis and treatment of venous thromboembolism (deep vein thrombosis, pulmonary embolism),Treatment of atrial fibrillation with embolization,Treatment of acute coronary syndromes (e.g., unstable angina, non-ST-elevation myocardial infarction),Prevention of clotting in arterial and cardiac surgery, hemodialysis, and extracorporeal circuits
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
5,000 units IV bolus, followed by continuous IV infusion of 18 units/kg/hr (initial based on actual body weight) for treatment of venous thromboembolism; or 5,000 units subcutaneously every 8-12 hours for prophylaxis of deep vein thrombosis. Titrate to a PTT 1.5-2.5 times control.
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
Terminal half-life: 1-2 hours (dose-dependent; mean 1.5 hours). Clinical context: Prolonged in hepatic/renal insufficiency; obesity (increased Vd). IV bolus: 30-60 min; continuous infusion: 1-2 hours.
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Heparin undergoes desulfation and partial depolymerization in the liver and reticuloendothelial system; primarily cleared by the kidneys.
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Renal: 40% as unchanged drug; reticuloendothelial system (liver, spleen): 60% metabolized to low molecular weight forms, then renally eliminated.
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
High, >95% bound to antithrombin III, albumin, and other plasma proteins.
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
0.04-0.06 L/kg (confined to plasma; does not cross placenta). Clinical meaning: Low Vd reflects limited extravascular distribution; predominantly intravascular.
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
SC: 20-30% (due to first-pass hepatic metabolism and local inactivation).
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
No standard dose adjustment for GFR; however, close monitoring of a PTT and for bleeding is recommended in severe renal impairment (Cr Cl <30 m L/min) due to increased risk of accumulation.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
No specific dose adjustment based on Child-Pugh class; use with caution in hepatic disease due to decreased clearance and increased risk of bleeding. Monitor a PTT and clinical response.
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
Loading dose: 75-100 units/kg IV over 10 minutes. Maintenance infusion: For age ≤1 year: 28 units/kg/hr; age >1 year: 20 units/kg/hr; adjust to achieve a PTT of 60-85 seconds or anti-Xa level of 0.3-0.7 units/m L.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
Increased risk of bleeding; consider lower initial infusion rates (e.g., 12-15 units/kg/hr) and more frequent a PTT monitoring. Use caution due to age-related renal function decline and concurrent medications.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
Spinal or epidural hematomas, including subsequent paralysis, may occur in patients anticoagulated with heparin who receive neuraxial anesthesia or undergo spinal puncture. Risk is increased by indwelling epidural catheters, concomitant use of drugs affecting hemostasis (e.g., NSAIDs, platelet inhibitors, anticoagulants), traumatic or repeated puncture. Monitor for signs/symptoms of neurological impairment.
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
Risk of hemorrhage, especially in patients with bleeding disorders, recent surgery, or concurrent use of antiplatelet agents or anticoagulants. Monitor platelet counts for heparin-induced thrombocytopenia (HIT). May cause hyperkalemia by suppressing aldosterone secretion. Use with caution in hepatic or renal impairment. Avoid intramuscular injection.
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Hypersensitivity to heparin or pork products, history of heparin-induced thrombocytopenia (HIT), active major bleeding (except when due to disseminated intravascular coagulation), severe thrombocytopenia, inability to perform adequate coagulation monitoring.
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
No significant food interactions. Heparin is administered parenterally and does not interact with dietary components. Vitamin K-rich foods (e.g., leafy greens) do not affect heparin activity.
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
Heparin does not cross the placenta; no known teratogenic risk. First trimester: No increased risk of major malformations. Second/third trimesters: Risk of maternal hemorrhage, placental abruption, or preterm labor if anticoagulation is excessive. No direct fetal toxicity.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
Heparin is not excreted into breast milk due to high molecular weight and poor oral bioavailability. Considered safe during breastfeeding; M/P ratio is not applicable (undetectable in milk).
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
Pregnancy increases volume of distribution and renal clearance, possibly requiring higher doses (e.g., 10-20% increase) to achieve therapeutic a PTT. Monitor a PTT frequently (e.g., weekly or with dose changes) and adjust accordingly. No specific dose conversion for IV to subcutaneous; use weight-based dosing.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
Heparin flushes (5000 U/m L) are used for catheter patency only; do not use therapeutic dosing. Verify concentration before administration. Flush volume should match catheter lumen volume. Monitor for bleeding risk in patients with thrombocytopenia or coagulation disorders. Use preservative-free formulation in neonates.
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
This medication is used to keep your IV line or catheter from clotting.,It contains heparin and will be given by a healthcare professional.,Tell your doctor if you have a history of heparin-induced thrombocytopenia (HIT) or if you take blood thinners like warfarin.,Report any unusual bleeding, bruising, or pain at the IV site immediately.,You may need regular blood tests to monitor your platelet count.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, answered by our medical review team.
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% is a Electrolyte that works by Heparin binds to antithrombin III, accelerating its inactivation of thrombin (factor IIa) and factor Xa, thereby inhibiting coagulation.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% is: 5,000 units IV bolus, followed by continuous IV infusion of 18 units/kg/hr (initial based on actual body weight) for treatment of venous thromboembolism; or 5,000 units subcutaneously every 8-12 hours for prophylaxis of deep vein thrombosis. Titrate to a PTT 1.5-2.5 times control.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% is classified as Category A/B. Heparin does not cross the placenta; no known teratogenic risk. First trimester: No increased risk of major malformations. Second/third trimesters: Risk of maternal hemorrhage, pla. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.